Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Hate to post this but it's life. Sorrento Therape

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155540
(Total Views: 978)
Posted On: 07/20/2020 2:53:00 PM
Posted By: HCIT
Hate to post this but it's life. Sorrento Therapeutics, also working on a vaccine, just got clearance from the FDA for a anti Inflamatory drug but it's only 40 patients & placebo: reEDIDTED

The biotech believes its drug could get patients out of the ICU sooner
By Jonathan WosenBiotech reporter
July 20, 2020
8:17 AM

San Diego biotech Sorrento Therapeutics announced Monday that it has received Food and Drug Administration clearance for a COVID-19 trial that could begin as soon as August.

Sorrento’s experimental drug, Abivertinib, shuts off two cellular signals that can cause inflammation. Unchecked inflammation, known as cytokine storms, are deadly for COVID-19 patients whose lungs have filled with fluid and dead cells.

“The drug hopefully will let patients out of the ICU and go back to their normal lives,” said Mark Brunswick, Sorrento’s senior vice president of regulatory affairs.

The upcoming trial will enroll 40 COVID-19 patients who are ill enough to be in the intensive care unit but are not yet on a ventilator. Half of patients will get the experimental drug, while the other half will get a placebo. Brunswick says that the company should know within three weeks of the trial’s start whether the drug is safe and if it helps patients leave the ICU sooner.

Pharma giant AstraZeneca has a drug that works similarly by targeting one of the same two signals Sorrento’s drug blocks. Scientists reported in June that AstraZeneca’s drug reduced inflammation in hospitalized COVID-19 patients. That bodes well for Sorrento, according to Raghuram Selvaraju, a research analyst for investment bank H.C. Wainwright & Co.

The AstraZeneca announcement, Selvaraju wrote, “only enhances the appeal of Sorrento’s candidate, in our view.”

Sorrento licensed Abivertinib from fellow San Diego biotech ACEA Therapeutics, which gives the company exclusive rights to use the drug outside of China. Sorrento also plans to test whether the drug reduces excess inflammation triggered by some cancer drugs.
LINK: https://www.sandiegouniontribune.com/business...d-19-trial

GLTA

HCIT


(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


https://media.gettyimages.com/photos/the-grea...wdoE_swYM=




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us